Interclade Neutralization and Enhancement of Human Immunodeficiency Virus Type 1 Identified by an Assay Using HeLa Cells Expressing Both CD4 Receptor and CXCR4/CCR5 Coreceptors

Journal of Infectious Diseases

Volumn 189, Issue 2, 2004, Pages 322-327

  Barin, Francis ^a,e   Brunet, Sylvie ^a   Brand, Denys ^a   Moog, Christiane ^b   Peyre, Robert ^a   Damond, Florence ^c   Charneau, Pierre ^d   Barre Sinoussi, Françoise ^d  

^a UNIVERSITÉ DE TOURS   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d INSTITUT PASTEUR   (France)

^e CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CELL ASSAY; CELL LINE; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACZ GENE; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION;

ANTIGENS, CD4; HELA CELLS; HIV ANTIBODIES; HIV-1; HUMANS; NEUTRALIZATION TESTS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 0742290081     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380099     Document Type: Article

References (15)

1. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-30.
2. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-7.
3. Montefiori DC, Evans TG. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses 1999; 15:689-98.
4. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial sero-conversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71:3734-41.
5. McLain L, Armstrong SJ, Dimmock NJ. Neutralization titres of HIV-1-specific monoclonal antibodies vary according to the batch of primary human peripheral blood lymphocytes, but do not vary coordinately. J Virol Methods 1997; 67:69-76.
6. Verrier FC, Chameau P, Altmeyer R, Laurent S, Borman AM, Girard M. Antibodies to several conformation-dependent epitopes of gp120/ gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. Proc Natl Acad Sci USA 1997; 94:9326-31.
7. Vodicka MA, Goh WC, Wu LI, et al. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997; 233:193-8.
8. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999; 73:8966-74.
9. Spenlehauer C, Gordon CA, Trkola A, Moore JP. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 2001; 280:292-300.
10. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-60.
11. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70:445-58.
12. Moore JP, Parren PWHI, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001; 75:5721-9.
13. Weber J, Fenyö EM, Beddows S, Kaleebu P, Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996; 70:7827-32.
14. Charneau P, Mirambeau G, Roux P, Paulous S, Bue H, Clavel F. HIV-1 reverse transcription: a termination step at the center of the genome. J Mol Biol 1994; 241:651-62.
15. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493-7.